MCID: ANV001
MIFTS: 46

Anovulation

Categories: Endocrine diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anovulation

MalaCards integrated aliases for Anovulation:

Name: Anovulation 11 53 43 14 71 75 33

Classifications:



External Ids:

Disease Ontology 11 DOID:3781
MeSH 43 D000858
NCIt 49 C34388
SNOMED-CT 68 34571000
ICD11 33 563648258
UMLS 71 C0003128

Summaries for Anovulation

Disease Ontology: 11 An ovarian disease that is characterized by the absence of ovulation.

MalaCards based summary: Anovulation is related to hyperprolactinemia and galactorrhea. An important gene associated with Anovulation is INS (Insulin), and among its related pathways/superpathways are Signal Transduction and Metabolism of steroids. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia: 75 Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation... more...

Related Diseases for Anovulation

Diseases related to Anovulation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 hyperprolactinemia 30.9 SHBG PRL INS IGF1 GNRH1 CGA
2 galactorrhea 30.9 PRL IGF1
3 ovarian hyperstimulation syndrome 30.4 SHBG INS GNRH1 FSHR FSHB CYP19A1
4 endometriosis 30.3 IGFBP1 GNRH1 FSHR CYP19A1 CGA
5 pituitary gland disease 30.3 PRL INS IGF1 GNRH1 CRH CGA
6 pituitary-dependent cushing's disease 30.2 PRL CRH
7 sexual health disorder 30.2 SHBG PRL GNRH1
8 ovarian cyst 30.2 SHBG PRL GNRH1 CYP19A1 CRP CGA
9 central diabetes insipidus 30.2 PRL IGF1 GNRH1
10 hyperandrogenism 30.2 SRD5A1 SHBG PRL INS IGFBP1 IGF1
11 diabetes insipidus 30.2 PRL INS CRH
12 graves disease 1 30.2 SHBG INS CRP
13 infertility 30.2 SHBG PRL LEP IGFBP1 GNRH1 FSHR
14 polycystic ovary syndrome 30.1 SRD5A1 SHBG PRL LEP INS IGFBP1
15 empty sella syndrome 30.1 PRL INS IGF1 GNRH1
16 hyperinsulinism 30.1 SHBG LEP INS IGFBP1 IGF1 GNRH1
17 premature ovarian failure 1 30.1 PRL GNRH1 FSHR BMP15
18 46,xx sex reversal 1 30.1 SRD5A1 FSHR BMP15
19 pituitary adenoma 30.0 PRL IGF1 GNRH1 GHRL CRH
20 uremia 30.0 LEP INS CRP
21 amenorrhea 30.0 SHBG PRL LEP INS IGF1 GNRH1
22 precocious puberty, male-limited 30.0 GNRH1 FSHR CYP21A2 CYP19A1
23 hypogonadism 30.0 SHBG PRL LEP INS IGF1 GNRH1
24 acanthosis nigricans 30.0 SHBG LEP INS IGF1
25 bone resorption disease 30.0 INS IGF1 CRP
26 endometrial cancer 30.0 SHBG LEP INS IGFBP1 IGF1 GNRH1
27 endogenous depression 30.0 PRL INS GNRH1 CRP CRH
28 leptin deficiency or dysfunction 29.9 LEP INS IGF1 GNRH1 GHRL CRP
29 prolactinoma 29.9 SHBG PRL INS IGF1 GNRH1 CYP19A1
30 alopecia, androgenetic, 1 29.9 SRD5A1 SHBG CYP21A2 CYP19A1
31 alopecia 29.9 SRD5A1 SHBG PRL IGF1 CYP19A1
32 type 1 diabetes mellitus 29.9 LEP INS IGFBP1 IGF1 GHRL
33 vaginal discharge 29.8 IGFBP1 HP GNRH1 CYP19A1 CRP
34 hyperglycemia 29.8 LEP INS IGF1 GHRL
35 insulin-like growth factor i 29.8 SHBG PRL LEP INS IGFBP1 IGF1
36 abdominal obesity-metabolic syndrome 1 29.8 LEP INS IGFBP1 GHRL
37 androgenic alopecia 29.8 SRD5A1 SHBG PRL INS IGF1 CYP19A1
38 spermatogenic failure 29.6 SHBG PRL GNRH1 FSHR FSHB CYP21A2
39 ovarian disease 29.6 SHBG PRL LEP INS IGFBP1 IGF1
40 lipid metabolism disorder 29.6 SHBG LEP INS IGF1 GHRL CYP21A2
41 anorexia nervosa 29.5 SHBG PRL LEP INS IGFBP1 IGF1
42 hypothyroidism 29.4 SHBG PRL LEP INS IGF1 GNRH1
43 prediabetes syndrome 29.4 SHBG LEP INS IGFBP1 IGF1 GHRL
44 type 2 diabetes mellitus 29.4 SHBG PRL LEP INS IGFBP1 IGF1
45 acne 29.4 SRD5A1 SHBG PRL LEP INS IGF1
46 hypopituitarism 29.4 SHBG PRL LEP INS IGF1 GNRH1
47 conn's syndrome 29.3 PRL LEP INS IGF1 GNRH1 GHRL
48 chronic kidney disease 29.3 LEP INS IGFBP1 IGF1 HP GHRL
49 gestational diabetes 29.3 SHBG PRL LEP INS IGFBP1 IGF1
50 glucose intolerance 29.3 SHBG PRL LEP INS IGFBP1 IGF1

Graphical network of the top 20 diseases related to Anovulation:



Diseases related to Anovulation

Symptoms & Phenotypes for Anovulation

GenomeRNAi Phenotypes related to Anovulation according to GeneCards Suite gene sharing:

25 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.26 CYP21A2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.26 LEP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.26 CYP21A2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.26 LEP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.26 LEP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.26 IGF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.26 LEP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.26 IGF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.26 CYP21A2 IGF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.26 CYP21A2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.26 BMP15 CYP21A2 IGF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.26 IGF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.26 IGF1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.26 SHBG
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.26 IGF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.26 CYP21A2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.26 CYP21A2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.26 SHBG
19 Increased shRNA abundance (Z-score > 2) GR00366-A-193 10.26 IGF1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.26 LEP
21 Increased shRNA abundance (Z-score > 2) GR00366-A-203 10.26 CYP21A2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-206 10.26 CYP21A2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.26 SHBG
24 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.26 CYP21A2 IGF1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.26 CYP21A2 LEP
26 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.26 LEP
27 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.26 IGF1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.26 SHBG
29 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.26 SHBG
30 Increased shRNA abundance (Z-score > 2) GR00366-A-55 10.26 LEP
31 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.26 CYP21A2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.26 BMP15
33 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.26 CYP21A2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.26 BMP15
35 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.26 IGF1
36 no effect GR00402-S-1 10.21 AMHR2 BMP15 CGA CRH CRP CYP19A1
37 no effect GR00402-S-2 10.21 AMHR2 BMP15 CRH CRP CYP19A1 CYP21A2

MGI Mouse Phenotypes related to Anovulation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 AMHR2 CGA CRH CRP CYP19A1 FSHB
2 endocrine/exocrine gland MP:0005379 10.1 AMHR2 BMP15 CGA CRH CYP19A1 FSHB
3 renal/urinary system MP:0005367 10.09 AMHR2 CRH CYP19A1 GNRH1 HP IGF1
4 neoplasm MP:0002006 10.06 AMHR2 FSHR GNRH1 HP IGF1 LEP
5 liver/biliary system MP:0005370 10.01 CRH CYP19A1 GNRH1 HP IGFBP1 INS
6 immune system MP:0005387 10 AMHR2 CRH CRP CYP19A1 CYP21A2 FSHR
7 adipose tissue MP:0005375 9.91 CRH CYP19A1 FSHR GHRL IGF1 INS
8 reproductive system MP:0005389 9.73 AMHR2 BMP15 CGA CYP19A1 FSHB FSHR
9 integument MP:0010771 9.36 AMHR2 CRH CYP19A1 CYP21A2 FSHR GNRH1

Drugs & Therapeutics for Anovulation

Drugs for Anovulation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
2
Polyestradiol phosphate Approved Phase 4 28014-46-2
3
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
4
Follitropin Approved, Vet_approved Phase 4 97048-13-0, 146479-72-3, 9002-68-0 62819
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
7
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
8
Clomifene Approved, Investigational Phase 4 911-45-5 2800
9
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
10
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
11
Enclomiphene Investigational Phase 4 15690-57-0 1548953
12 Contraceptive Agents Phase 4
13 Hormones Phase 4
14 Estradiol 3-benzoate Phase 4
15 Estradiol 17 beta-cypionate Phase 4
16 Calcium, Dietary Phase 4
17 Chelating Agents Phase 4
18 Anticoagulants Phase 4
19 Hypoglycemic Agents Phase 4
20 Pharmaceutical Solutions Phase 4
21 Citrate Phase 4
22 Estrogens Phase 4
23 Estrogen Receptor Modulators Phase 4
24 Estrogen Receptor Antagonists Phase 4
25 Estrogen Antagonists Phase 4
26 Selective Estrogen Receptor Modulators Phase 4
27 Zuclomiphene Phase 4
28 Aromatase Inhibitors Phase 4
29 Hormone Antagonists Phase 4
30 Chorionic Gonadotropin Phase 4
31 Follicle Stimulating Hormone Phase 4
32
Calcium Nutraceutical Phase 4 7440-70-2 271
33
Desogestrel Approved Phase 3 54024-22-5 40973
34
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 10631 6279
35
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
36 Contraceptives, Oral, Hormonal Phase 3
37 Contraceptives, Oral Phase 3
38 Contraceptive Agents, Male Phase 3
39 Progestins Phase 3
40 Tin Fluorides Phase 3
41
Sildenafil Approved, Investigational Phase 2 139755-83-2, 171599-83-0 5212 135398744
42
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
43
Inositol Approved, Investigational, Withdrawn Phase 2 87-89-8
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763
46 Antineoplastic Agents, Hormonal Phase 2
47 Phosphodiesterase Inhibitors Phase 2
48 Phosphodiesterase 5 Inhibitors Phase 2
49 Vasodilator Agents Phase 2
50 Folate Phase 2

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial Unknown status NCT02186782 Phase 4 Clomiphene citrate and Estradiol;Clomiphene citrate and Placebo
2 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
3 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
4 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Unknown status NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
5 Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin
6 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
7 Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial Completed NCT00558077 Phase 4 Metformin plus clomiphene citrate
8 Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study Completed NCT01004068 Phase 4 Clomiphene citrate
9 Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study. Completed NCT00473538 Phase 4
10 Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
11 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Completed NCT02703649 Phase 4 Letrozole
12 Ovarian Function in Women With Polycystic Ovary Syndrome Completed NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
13 Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation Recruiting NCT05206448 Phase 4 Letrozole;Clomiphene Citrate
14 Pilot Study: Role of Dietary Fiber in PCOS Anovulation Terminated NCT00703092 Phase 4 Fiber-Stat
15 A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
16 The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial Unknown status NCT02103764 Phase 3 Desogestrel;Medroxyprogesterone acetate
17 A Phase III Clinical Study for the Comparison Evaluation of DA-3801 and Gonal-F® in Infertile Female Patients With Chronic Anovulation Syndrome Completed NCT01820728 Phase 3 DA-3801 Injection;Gonal-F®
18 Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa Completed NCT01653743 Phase 3 MSJ-0011;urinary hCG (u-hCG);Follitropin alpha
19 Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation Completed NCT02335879 Phase 3
20 Intrauterine Infusion of Autologous Platelet-rich Plasma to Prevent a Thin Endometrium in Infertile Women Undergoing Clomiphene Citrate Therapy: a Pilot Prospective Self-controlled Trial Completed NCT03770026 Phase 2, Phase 3 clomiphene citrate;Saline cervical flushing
21 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
22 Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial Completed NCT01008319 Phase 3 clomiphene citrate
23 A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate Completed NCT01923194 Phase 3 Highly Purified Urofollitropin;Recombinant Human Follitropin Alfa
24 An Open, Randomized, Parallel-Group, Multicentric, Comparative Study of Letrozole With Clomiphene Citrate for Induction of Ovulation in Anovulatory Infertility. Completed NCT00610077 Phase 3 Letrozole;Clomiphene citrate
25 Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome Unknown status NCT02551367 Phase 2 Letrozole;Clomiphene citrate;hcg hormone
26 Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility:A Clinical Research of "Same Treatment for Different Diseases" Unknown status NCT03709849 Phase 2 experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo;control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
27 Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With HMG in PCOs Patients With Previous Clomiphene Citrate (CC)-Resistant Anovulation Completed NCT00947713 Phase 1, Phase 2 low dose human chorionic gonadotropin;Clomiphen citrate plus HMG
28 A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction Completed NCT00213148 Phase 2 Anastrozole 1 mg;Anastrozole 5 mg;Anastrozole 10 mg;Clomiphene Citrate 50 mg;Clomiphene Citrate 100 mg
29 The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial. Completed NCT02663830 Phase 2 Sildenafil & clomiphene citrate;clomiphene only
30 Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double Blind Dose Ranging RCT (INSUPP-PCOS) Recruiting NCT03864068 Phase 2 Inositol
31 Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene Completed NCT01289756 Phase 1 Clomiphene;clomiphene and paroxetine;clomiphene and clarithromycin
32 Laparoscopic Ovarian Drilling Versus Gonadotrophins for Anovulatory Polycystic Ovary Syndrome Resistant to First Line Ovulation Induction: a Randomized Controlled Trial. Unknown status NCT04325295 Recombinant FSH (rFSH)
33 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families Unknown status NCT00665171
34 Dynamic Changes in the Serum Anti-Müllerian Hormone Level During Low-Dose recFSH Administration Further Support Its Role in the Anovulation of Polycystic Ovary Syndrome Completed NCT00492882 usual administration of exogenous recombinant FSH
35 Serum Kisspeptin Levels in Infertile Women Due to Anovulatory Cycles, Unexplained Infertility or Male Subfertility: A Prospective Observational Study Completed NCT03018314
36 Visceral Fat Area and Other Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome Completed NCT02269306 clomiphen citrate
37 Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome Completed NCT03088046 Micronized Progesterone
38 Effect of Bright Light on Sex Hormones and Ovulation in Humans Completed NCT00327366
39 Clinical Investigation of the OV-Watch™ Personal Fertility Monitor for Women Undergoing Ovulation Induction With Clomiphene Citrate. Completed NCT00239603
40 Organochlorine Compounds and Menstrual Cycle Function Completed NCT00011388
41 Dietary Energy Requirements in Physically Active Men and Women, Objective 4B: Effects of Gynecological Age on LH Sensitivity to Energy Availability Completed NCT00260286
42 Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial Completed NCT02710981 clomiphene citrate;Sildenafil vaginal gel
43 Protocol for Drug Use Investigation of Follistim Injection Completed NCT00920634 Follitropin beta
44 Transvaginal Ultrasound-Guided Ovarian Interstitial Laser Treatment in Anovulatory Women With Polycystic Ovarian Syndrome: A Randomized Prospective Study on the Effect of Laser Dose Used on the Outcome Completed NCT00643708
45 A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women. Completed NCT00292799 Orlistat Vs Metformin
46 The Effect of Weight Reduction Surgery on Ovarian Function in Obese Anovulatory Patients Completed NCT00292773
47 Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients Completed NCT02544776 Clomifene citrate ( clomid 50 mg );Amlodipine
48 The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes in Obese, Subfertile Women Completed NCT01894074
49 To Study The Influence Of Pharmacogenomics Factors On Pharmacokinetics And Pharmacodynamics Of Clomiphene In Asian Normogonadotrophic Anovulatory Patients. Completed NCT02548039
50 A Randomized Double-blind Controlled Trial on the Effect of Vitamin D on Ovulation Rate of Women With Polycystic Ovary Syndrome Recruiting NCT04650880

Search NIH Clinical Center for Anovulation

Cochrane evidence based reviews: anovulation

Genetic Tests for Anovulation

Anatomical Context for Anovulation

Organs/tissues related to Anovulation:

MalaCards : Ovary, Pituitary, Brain, Breast, Placenta, Thyroid, Bone

Publications for Anovulation

Articles related to Anovulation:

(show top 50) (show all 2862)
# Title Authors PMID Year
1
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. 53 62
20096985 2010
2
Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant. 53 62
19782351 2010
3
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 53 62
20091537 2010
4
Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). 53 62
20092643 2010
5
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. 53 62
19906783 2010
6
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 53 62
19821299 2009
7
Selective impairment in glycogen synthase kinase-3 and mitogen-activated protein kinase phosphorylation: comparisons with the hyperandrogenic and the hyperinsulinemic rats. 53 62
19027112 2009
8
A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. 53 62
19470707 2009
9
WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome. 53 62
19588338 2009
10
Androgen circle of polycystic ovary syndrome. 53 62
19279033 2009
11
The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. 53 62
19413702 2009
12
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. 53 62
19370625 2009
13
Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome. 53 62
19141577 2009
14
Drug treatments for polycystic ovary syndrome. 53 62
19405411 2009
15
Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance. 53 62
19243758 2009
16
Polycystic ovary syndrome in the adolescent. 53 62
19344852 2009
17
Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. 53 62
19212122 2009
18
PCOS and cancer risk. 53 62
20067879 2009
19
Pancreatic beta-cells dysfunction in polycystic ovary syndrome. 53 62
19078872 2008
20
Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). 53 62
18505468 2008
21
Cardiovascular risk in women with polycystic ovary syndrome. 53 62
18799960 2008
22
Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. 53 62
18602948 2008
23
What every physician should know about polycystic ovary syndrome. 53 62
18844713 2008
24
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 53 62
18639784 2008
25
Ovulation triggers in anovulatory women undergoing ovulation induction. 53 62
18646175 2008
26
Does polycystic ovary syndrome start in childhood? 53 62
18552753 2008
27
The role of mullerian inhibiting substance in female reproduction. 53 62
18460940 2008
28
Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. 53 62
18382906 2008
29
A case of Cushing's syndrome presenting as endometrial hyperplasia. 53 62
18363281 2008
30
Structural evaluation of type 3 dopaminergic receptor gene (DRD3) in chronic anovulatory women. 53 62
18393218 2008
31
Polycystic ovary syndrome in the Indian Subcontinent. 53 62
18181079 2008
32
HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? 53 62
18729532 2008
33
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 53 62
17984248 2007
34
Expression of leptin long-form receptor mRNA in luteinized granulosa cells of obese women with polycystic ovary syndrome. 53 62
17828512 2007
35
[Mechanism of action of insulin sensitizer agents in the treatment of polycystic ovarian syndrome]. 53 62
17547089 2007
36
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 53 62
17426408 2007
37
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? 53 62
17145645 2006
38
Up-regulation of the phosphatidylinositol 3-kinase/protein kinase B pathway in the ovary of rats by chronic treatment with hCG and insulin. 53 62
16899578 2006
39
Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. 53 62
17185789 2006
40
The frequency of insulin resistance calculated upon the basis of a fasting glucose to insulin ratio and characteristics of insulin resistant women with polycystic ovary syndrome. 53 62
16985482 2006
41
Metabolic effects of obesity on reproduction. 53 62
16790096 2006
42
Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. 53 62
16522691 2006
43
Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. 53 62
16606451 2006
44
Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. 53 62
16338908 2006
45
Polycystic ovary syndrome: the influence of environmental and genetic factors. 53 62
16728382 2006
46
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. 53 62
16263811 2006
47
Effect of leptin administration on ovulation in food-restricted rhesus monkeys. 53 62
17106186 2006
48
[Polycystic ovary syndrome associated neoplasms]. 53 62
16444364 2005
49
Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria. 53 62
16219952 2005
50
Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. 53 62
15890737 2005

Variations for Anovulation

Expression for Anovulation

Search GEO for disease gene expression data for Anovulation.

Pathways for Anovulation

Pathways related to Anovulation according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 13.43 AMHR2 CGA CRH FSHB FSHR GHRL
2
Show member pathways
12.36 SRD5A1 INS CYP21A2 CYP19A1 CGA
3
Show member pathways
11.87 FSHR FSHB CRH CGA
4
Show member pathways
11.87 LEP INS IGF1 GHRL FSHB CGA
5 11.65 LEP INS IGF1
6
Show member pathways
11.54 SRD5A1 CYP21A2 CYP19A1 CGA
7 11.44 INS GNRH1 GHRL
8 11.3 PRL LEP INS
9 11.26 IGF1 CYP19A1 CGA
10 10.56 PRL LEP INS GHRL
11 10 GNRH1 FSHR FSHB CGA

GO Terms for Anovulation

Cellular components related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.12 BMP15 CGA CRH CRP FSHB GHRL
2 extracellular space GO:0005615 9.77 BMP15 CGA CRH CRP FSHB GHRL
3 follicle-stimulating hormone complex GO:0016914 9.46 FSHB CGA

Biological processes related to Anovulation according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.34 PRL LEP INS IGF1 FSHB CGA
2 positive regulation of MAPK cascade GO:0043410 10.21 LEP INS IGF1 GHRL
3 steroid biosynthetic process GO:0006694 10.07 SRD5A1 CYP21A2 CYP19A1
4 hormone-mediated signaling pathway GO:0009755 10.06 GHRL FSHR CGA
5 acute-phase response GO:0006953 9.99 INS HP CRP
6 female pregnancy GO:0007565 9.97 PRL LEP FSHB CRH
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.92 FSHR IGF1 INS LEP
8 glucocorticoid biosynthetic process GO:0006704 9.88 CRH CYP21A2
9 female gonad development GO:0008585 9.88 FSHR CYP19A1 AMHR2
10 female genitalia development GO:0030540 9.87 CYP19A1 SRD5A1
11 bone mineralization involved in bone maturation GO:0035630 9.86 IGF1 LEP
12 ovarian follicle development GO:0001541 9.84 FSHR FSHB BMP15
13 androgen catabolic process GO:0006710 9.83 SRD5A1 CYP19A1
14 positive regulation of corticotropin secretion GO:0051461 9.8 CRH GHRL
15 positive regulation of cortisol secretion GO:0051464 9.78 CRH GHRL
16 negative regulation of glucagon secretion GO:0070093 9.76 CRH LEP
17 positive regulation of steroid biosynthetic process GO:0010893 9.73 FSHB CGA
18 Sertoli cell proliferation GO:0060011 9.72 FSHR FSHB
19 female gamete generation GO:0007292 9.63 FSHR FSHB BMP15
20 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.56 GHRL CRH
21 regulation of protein phosphorylation GO:0001932 9.43 LOX LEP IGF1 FSHR
22 follicle-stimulating hormone signaling pathway GO:0042699 9.1 FSHR FSHB CGA

Molecular functions related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.53 PRL LEP INS IGF1 GNRH1 GHRL
2 follicle-stimulating hormone activity GO:0016913 9.26 FSHB CGA

Sources for Anovulation

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....